Exagen inc. and johns hopkins university announce license agreement for novel patented lupus nephritis biomarkers

San diego, california, nov. 09, 2023 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing solutions, and johns hopkins university jointly announced today the execution of an exclusive license agreement. exagen will focus on the development of novel patented biomarkers for therapeutic management of patients with lupus nephritis.
XGN Ratings Summary
XGN Quant Ranking